Sonal Singh to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Sonal Singh has written about Diabetes Mellitus, Type 2.
Connection Strength
3.392
-
Singh S, Wright EE, Kwan AY, Thompson JC, Syed IA, Korol EE, Waser NA, Yu MB, Juneja R. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017 02; 19(2):228-238.
Score: 0.336
-
Singh S, Suchard MA. Pioglitazone Use and Risk of Bladder Cancer. JAMA. 2015 Dec 15; 314(23):2567-8.
Score: 0.314
-
Maruthur NM, Joy SM, Dolan JG, Shihab HM, Singh S. Use of the analytic hierarchy process for medication decision-making in type 2 diabetes. PLoS One. 2015; 10(5):e0126625.
Score: 0.302
-
Singh S. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy. Curr Diab Rep. 2014 Dec; 14(12):563.
Score: 0.292
-
Singh S. Glucagon-like peptide 1-based drugs and pancreatic safety--reply. JAMA Intern Med. 2013 Oct 28; 173(19):1843-4.
Score: 0.271
-
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013 Apr 08; 173(7):534-9.
Score: 0.261
-
Singh S, Segal JB. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Arch Intern Med. 2012 Jul 09; 172(13):1011-3.
Score: 0.248
-
Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011 Mar 17; 342:d1309.
Score: 0.226
-
Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2008 Sep; 7(5):579-85.
Score: 0.190
-
Singh S, Furberg CD. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart. 2009 Jan; 95(1):1-3.
Score: 0.189
-
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12; 298(10):1189-95.
Score: 0.177
-
Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007 Aug; 30(8):2148-53.
Score: 0.174
-
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018 09 01; 178(9):1190-1198.
Score: 0.095
-
Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):567-75.
Score: 0.075
-
Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014 Apr; 37(4):985-92.
Score: 0.068
-
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 May 03; 154(9):602-13.
Score: 0.056
-
Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. Thorax. 2011 May; 66(5):383-8.
Score: 0.056
-
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 06; 180(1):32-9.
Score: 0.048
-
Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011 Feb; 104(2):109-24.
Score: 0.014